Tests blood marker link to lung blood clots in ARDS
Treatments studied
Part of Lungs & breathing clinical trials.
This study looks at a blood marker (EV-TF) to see whether it helps predict pulmonary embolism—blood clots in the lungs—in people with ARDS who are in the ICU. Results may help doctors better identify who is at higher risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You were admitted to the ICU within the last 24 hours
- You have ARDS (a serious lung condition) diagnosed by standard criteria, including low oxygen on a ventilator and lung changes on imaging
- Your heart cause of lung symptoms has been ruled out by an echocardiogram
- The trial testing period starts before you have had a positive COVID-19 PCR in the breathing samples
- You are not already on full-dose (curative) blood-thinner treatment, ECMO, or certain blood-thinning treatments used with kidney-related purification before ICU
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for markers in the blood and signs of air trapped in the lung tissue of people with acute respiratory distress syndrome (ARDS). It uses CT scans to understand why air leaks happen and if certain lab tests can predict them.
This study is testing whether certain proteins in the blood (sRAGE, CC16, and Syndecan-1) can help predict if patients with severe chest trauma will develop a serious lung condition called ARDS or have a higher risk of death. By measuring these proteins early, doctors might be able to identify high-risk patients sooner and provide more targeted care.
This trial tests whether erythropoietin (EPO), a medicine that affects red blood cell production, can help clear extra fluid from the lungs in people with acute respiratory distress syndrome (ARDS). If it works, it could improve breathing and reduce lung fluid buildup during critical illness.
This trial tests a new treatment called IC14 for people in the hospital on a breathing machine for ARDS (a severe lung injury). The study aims to see if IC14, which blocks a protein involved in inflammation, can help the lungs heal faster.
This study looks for early markers in the blood that can predict a serious lung reaction called TRALI after a blood transfusion in ICU patients. It compares blood samples from different groups to find these markers, which could help prevent future reactions.
This study is for patients in the ICU with ARDS (a severe lung condition). It looks at biomarkers (special substances in your blood) to help understand different types of ARDS. You do not receive any treatment, but you help researchers learn more about the disease.
Hear when a new Acute Respiratory Distress Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.